SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms.
作者信息
Fabiani Emiliano, Falconi Giulia, Fianchi Luana, Criscuolo Marianna, Leone Giuseppe, Voso Maria Teresa
机构信息
Institute of Hematology, Università Cattolica del Sacro Cuore, Rome, Italy
Institute of Hematology, Università Cattolica del Sacro Cuore, Rome, Italy.
出版信息
Haematologica. 2014 Sep;99(9):e152-3. doi: 10.3324/haematol.2014.108159. Epub 2014 Jun 6.
Abstract
摘要
相似文献
1
SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms.
Haematologica. 2014 Sep;99(9):e152-3. doi: 10.3324/haematol.2014.108159. Epub 2014 Jun 6.
2
SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias.
Leukemia. 2013 Jun;27(6):1401-3. doi: 10.1038/leu.2013.35. Epub 2013 Feb 5.
3
SETBP1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
Pathol Res Pract. 2018 May;214(5):706-712. doi: 10.1016/j.prp.2018.03.010. Epub 2018 Mar 7.
4
SETBP1 mutations in juvenile myelomonocytic leukaemia and myelodysplastic syndrome but not in paediatric acute myeloid leukaemia.
Br J Haematol. 2014 Jan;164(1):156-9. doi: 10.1111/bjh.12595. Epub 2013 Oct 14.
5
SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.
Leukemia. 2015 Apr;29(4):847-57. doi: 10.1038/leu.2014.301. Epub 2014 Oct 13.
6
SETBP1 mutation analysis in 944 patients with MDS and AML.
Leukemia. 2013 Oct;27(10):2072-5. doi: 10.1038/leu.2013.145. Epub 2013 May 7.
7
Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
Oncotarget. 2016 Mar 22;7(12):14251-8. doi: 10.18632/oncotarget.7350.
8
Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignancies.
J Cancer Res Clin Oncol. 2017 Dec;143(12):2511-2519. doi: 10.1007/s00432-017-2518-z. Epub 2017 Sep 14.
9
Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression.
Am J Hematol. 2014 Feb;89(2):181-6. doi: 10.1002/ajh.23611. Epub 2013 Nov 20.
10
SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
Leukemia. 2013 Sep;27(9):1852-60. doi: 10.1038/leu.2013.133. Epub 2013 Apr 30.
引用本文的文献
1
Whole-genome sequencing combined RNA-sequencing analysis of patients with mutations in SET binding protein 1.
Front Neurosci. 2022 Sep 7;16:980000. doi: 10.3389/fnins.2022.980000. eCollection 2022.
2
Molecular Pathogenesis of -Negative Atypical Chronic Myeloid Leukemia.
Front Oncol. 2021 Nov 11;11:756348. doi: 10.3389/fonc.2021.756348. eCollection 2021.
3
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia.
Hemasphere. 2020 Nov 6;4(6):e497. doi: 10.1097/HS9.0000000000000497. eCollection 2020 Dec.
4
The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution.
Leukemia. 2019 Dec;33(12):2842-2853. doi: 10.1038/s41375-019-0479-8. Epub 2019 May 14.
5
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub.
Nat Commun. 2018 Jun 6;9(1):2192. doi: 10.1038/s41467-018-04462-8.
6
Therapy-associated myelodysplastic syndrome with monosomy 7 arising in a Muir-Torre Syndrome patient carrying mutation.
Mol Clin Oncol. 2018 Feb;8(2):306-309. doi: 10.3892/mco.2017.1532. Epub 2017 Dec 8.
7
dysregulation in congenital disorders and myeloid neoplasms.
Oncotarget. 2017 Apr 19;8(31):51920-51935. doi: 10.18632/oncotarget.17231. eCollection 2017 Aug 1.
8
Somatic SETBP1 mutations in myeloid neoplasms.
Int J Hematol. 2017 Jun;105(6):732-742. doi: 10.1007/s12185-017-2241-1. Epub 2017 Apr 26.
9
Overlapping SETBP1 gain-of-function mutations in Schinzel-Giedion syndrome and hematologic malignancies.
PLoS Genet. 2017 Mar 27;13(3):e1006683. doi: 10.1371/journal.pgen.1006683. eCollection 2017 Mar.
10
Clonal evolution in therapy-related neoplasms.
Oncotarget. 2017 Feb 14;8(7):12031-12040. doi: 10.18632/oncotarget.14509.
本文引用的文献
1
Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression.
Am J Hematol. 2014 Feb;89(2):181-6. doi: 10.1002/ajh.23611. Epub 2013 Nov 20.
2
Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression.
Br J Haematol. 2013 Oct;163(2):235-9. doi: 10.1111/bjh.12491. Epub 2013 Jul 24.
3
Somatic SETBP1 mutations in myeloid malignancies.
Nat Genet. 2013 Aug;45(8):942-6. doi: 10.1038/ng.2696. Epub 2013 Jul 7.
4
SETBP1 mutation analysis in 944 patients with MDS and AML.
Leukemia. 2013 Oct;27(10):2072-5. doi: 10.1038/leu.2013.145. Epub 2013 May 7.
5
SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias.
Leukemia. 2013 Jun;27(6):1401-3. doi: 10.1038/leu.2013.35. Epub 2013 Feb 5.
6
Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia.
Haematologica. 2013 Jun;98(6):908-12. doi: 10.3324/haematol.2012.076729. Epub 2013 Jan 24.
7
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.
Nat Genet. 2013 Jan;45(1):18-24. doi: 10.1038/ng.2495. Epub 2012 Dec 9.
8
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases.
Leukemia. 2013 Apr;27(4):982-5. doi: 10.1038/leu.2012.267. Epub 2012 Sep 11.
9
Genetic pathways leading to therapy-related myeloid neoplasms.
Mediterr J Hematol Infect Dis. 2011;3(1):e2011019. doi: 10.4084/MJHID.2011.019. Epub 2011 May 16.
10
A syndrome of severe midface retraction, multiple skull anomalies, clubfeet, and cardiac and renal malformations in sibs.
Am J Med Genet. 1978;1(4):361-75. doi: 10.1002/ajmg.1320010402.
Zotero 插件